Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) headquartered in San Carlos, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.iovance.com
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patients immune system to eradicate cancer cells. The companys lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers.
